



# Yungjin Pharm. Co., Ltd.

Since its establishment in 1952, YUNGJIN PHARM. CO., LTD. has been a pioneer in the Korean domestic pharmaceutical industry for national economic development and improving public health with the lofty mission of saving humanity from disease and suffering through our medicines. As an affiliate of KT&G Group, YUNGJIN plays a pivotal role in the bio/pharmaceutical business within the group with outstanding drug production and R&D know-how, and has grown into a global pharmaceutical company by developing new products and expanding exports.

## Main Products

Product	Ingredient	Exporting Countries	Remarks
CEROCAPENE	Cefcapene Pivoxil	Worldwide	API, tab., fine gran.
CEFDITOREN	Cefditoren Pivoxil	Worldwide	API, tab., fine gran.
CEFMETAZOLE	Cefmetazole Sodium	Worldwide	API, inj.
CEFOTIAM	Cefotiam HCl/HCl+Na2CO3	Worldwide	API
CEFTRIAZONE	Ceftriaxone Sodium	Worldwide	inj.
CEFTAZIDIME	Ceftazidime Hydrate	Asia	inj.
CEFOXETIL	Cefpodoxime Proxetil	Asia	API, tab., DS
CEROFAZIL	Cefprozil Hydrate	Asia	tab., DS
CEFDINIR	Cefdinir Hydrate	Asia	API, tab., fine gran.
LOXOPROFEN	Loxoprofen Sodium	Worldwide	API
CANDESARTAN	Candesartan Cilexetil	Asia	API, tab.
FEBUXOSTAT	Febuxostat	Worldwide	API
LINEZOLIN	Linezolid	Worldwide	tab.
YUNGPENEM	Imipenem, Cilastatin	Worldwide	inj.
BAROSCON DOUBLE ACTION	Sodium alginate, calcium carbonate, sodium bicarbonate	Worldwide	susp.
Pediatric Complete Multivitamin	Multivitamins	Worldwide	syr.

## R&D Pipeline

Project Name	Therapeutic Area	Indication	Development Status				
			Research	Nonclinical	Phase I	Phase II	Phase III
YPL-001	Respiratory	COPD (Asthma)	[Progress bar]				
YRA-1909	Immunology	Rheumatoid Arthritis	[Progress bar]				
KL1333	Metabolic Disorder	Mitochondrial Disease	[Progress bar]				
YPN-005	Oncology	Cancer	[Progress bar]				
YPN-006	Oncology	Immuno-oncology	[Progress bar]				
YPI-005	Other Blood Related	Spinal Stenosis	[Progress bar]				
YPI-008	Cardiovascular	Hypertension Dyslipidemia	[Progress bar]				
YPI-009	Gastrointestinal	Gastroesophageal Reflux Disease	[Progress bar]				
YPI-010	Respiratory	Idiopathic Pulmonary Fibrosis	[Progress bar]				

CEO  
Chae Joon Lee

Location  
13, Olympic-ro 35da-gil, Songpa-gu, Seoul, 05510, Korea

- Specialty
1. NCE(Targeted cancer therapy, Cancer immunotherapy, Rare disease)
  2. IMD & Generic (Cephalosporins, Antipyretic-analgesics & Anti-inflammatory, CNS, Rare disease)
  3. API(Cephalosporins, Anti-hypertension, Anti-inflammatory, Analgesic)

Tel / Fax / E-mail  
T. 82-2-2041-8200  
F. 82-2-2041-8201